6th Aug 2008 16:00
Notification of Acquisition of Shares by Director/Person Discharging Managerial Responsibilities
Basingstoke, UK and Philadelphia, US - August 6, 2008 - Shire Limited , the global specialty biopharmaceutical company, announces that on August 6, 2008 it was notified by Mr. Graham Hetherington, Chief Financial Officer of the Company, of an acquisition on the same day of 4,000 ordinary shares of ‚£0.05 each ("Shares"). The Shares were acquired at a price of ‚£8.9618 per Share.
Following this transaction, Mr. Hetherington holds 4,000 Shares. In addition, Mr. Hetherington holds awards over 175,000 Shares, all of which are still to vest.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
T MayCompany Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE LIMITED
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
vendorRelated Shares:
Shire